Accessibility Menu
Zoetis logo

Zoetis(NYSE) ZTS

Current Price$75.12
Market Cap$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+176%
5 Year-59%
1 Year-48%
1 Month-3%
Zoetis last closing stock price
MetricPriceDate
Last closeUSD 76.202026-07-20
Zoetis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.78%USD 74.872026-07-13
1 month-2.51%USD 78.172026-06-18
3 month-35.07%USD 117.362026-04-21
Year to date-38.49%USD 123.882025-12-31
1 year-47.74%USD 145.802025-07-18
3 year-56.74%USD 176.142023-07-21
5 year-59.3%USD 187.222021-07-21
Since inception+176.04%USD 27.602013-02-01

Zoetis Financials at a Glance

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.51B

Net Income (TTM)

$2.64B

EPS (TTM)

$6.04

P/E Ratio

12.62

Dividend

$2.09

Beta (Volatility)

0.82 (Low)

Price

$75.12

Volume

137,058

Open

$75.66

Previous Close

$76.20

Daily Range

$74.57 - $76.35

52-Week Range

$71.47 - $160.48

Estimated Earnings Date

Aug 6, 2026

ZTS: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zoetis

Zoetis makes medicines and vaccines to keep pets and farm animals healthy. The company helps veterinarians and farmers find and treat animal diseases. Its products help animals live longer and ensure a safe food supply.

What Zoetis Sells

  • Companion Animal Products: Medicines, vaccines, and diagnostic tests for dogs, cats, and horses; accounts for 70% of revenue.
  • Livestock Products: Health solutions for cattle, swine, poultry, fish, and sheep; accounts for 29% of revenue.
  • Parasiticides: Products that prevent or kill parasites like fleas, ticks, and worms.
  • Dermatology: Specialized treatments for skin allergies and itching in dogs.
  • Animal Health Diagnostics: Tools and kits used for testing blood and urine samples in clinics.

Recent Moves and Milestones

  • Acquired Veterinary Pathology Group in 2025 to expand diagnostic lab services in the U.K. and Ireland.
  • Divested the medicated feed additive product portfolio and related assets on October 31, 2024.
  • Purchased a manufacturing site near Atlanta, Georgia in 2023 to increase future production capacity.
  • Acquired PetMedix Ltd and adivo GmbH in 2023 to develop new antibody therapies for pets.
  • Expanded the Abaxis portfolio in 2023 by adding artificial intelligence features to the Vetscan Imagyst platform.

A Global Health Network

The company operates 21 manufacturing sites and sells products in more than 100 countries. It uses a direct sales force of 3,900 employees to maintain relationships with veterinarians and livestock producers.

By the Numbers

  • Revenue reached $2.4 billion in Q4 2025, up 3% from Q4 2024.
  • Operating income rose to $826 million in Q4 2025, an 8% increase year-over-year.
  • Net income grew to $603 million in Q4 2025, up 3.8% from the previous year.
  • Free cash flow was $732 million in Q4 2025, up 6.2% from Q4 2024.
  • Research and development spending totaled $698 million for the full year 2025.

Bottom Line

Zoetis has transitioned from a division of Pfizer into an independent leader in animal healthcare. The company continues to evolve by combining traditional medicines with digital diagnostics and biotechnology.

AI Generated • Apr 18, 2026

Industry

Pharmaceuticals

Employees

14,500

CEO

Kristin C. Peck, MBA

Headquarters

Parsippany, NJ 07054, US

ZTS Financials

Key Financial Metrics (TTM)

Gross Margin

70.75%

Operating Margin

37.57%

Net Income Margin

27.79%

Return on Equity

62.41%

Return on Capital

28.05%

Return on Assets

17.44%

Earnings Yield

7.92%

Dividend Yield

2.74%

Payout Ratio

33.64%

Stock Overview

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

419.23M

Volume

137.06K

Avg. Volume

7.37M

Financials (TTM)

Gross Profit

$6.73B

Operating Income

$3.57B

EBITDA

$4.03B

Operating Cash Flow

$2.72B

Capital Expenditure

-$582.00M

Free Cash Flow

$2.14B

Cash & ST Invst.

$1.94B

Total Debt

$9.24B

Zoetis Performance Analysis

Zoetis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,080,000,0003.9%
20232023-12-31USD 8,544,000,0005.7%
20242024-12-31USD 9,256,000,0008.3%
20252025-12-31USD 9,467,000,0002.3%
Zoetis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.8%
Q32025-09-30-2.4%
Q42025-12-31-0.5%
Q12026-03-31-5.2%
Zoetis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.495.2%
20232023-12-31USD 5.0712.8%
20242024-12-31USD 5.477.8%
20252025-12-31USD 6.0210.2%
Zoetis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.2%
Q32025-09-301.2%
Q42025-12-31-16.0%
Q12026-03-313.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.26B

+1.9%

Gross Profit

$1.62B

+3.5%

Gross Margin

71.66%

N/A

Market Cap

$31.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.20M

N/A

Employees

14,500

N/A

Net Income

$601.00M

-4.8%

EBITDA

$939.00M

-5.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.94B

+12.7%

Total Debt

$9.24B

+36.9%

Accounts Receivable

$1.51B

+10.7%

Inventory

$2.55B

+7.8%

Long Term Debt

$9.24B

+71.1%

Short Term Debt

$0.00

-100.0%

Return on Assets

17.44%

N/A

Return on Invested Capital

27.27%

N/A

Free Cash Flow

$291.00M

-33.6%

Operating Cash Flow

$401.00M

-31.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IDXXIDEXX Laboratories, Inc.
$552.87-1.94%
HLNHaleon plc
$9.94-1.05%
ELANElanco Animal Health Incorporated
$25.48+1.35%
ARGXargenx SE
$871.79+3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.59+0.10%
NOKNokia
$10.62+0.05%
AALAmerican Airlines Group
$15.19+0.00%
HLHecla Mining
$15.15+0.06%

Questions About ZTS

What is the current price of Zoetis?

Zoetis is trading at $75.13 per share.

What is the 52-week range for Zoetis?

Over the past 52 weeks, Zoetis has traded between $71.47 and $160.48.

How much debt does Zoetis have?

As of the most recent reporting period, Zoetis reported total debt of $9.24B.

How much cash does Zoetis have on hand?

Zoetis reported $1.94B in cash and cash equivalents in its most recent financial results.

What is Zoetis’s dividend yield?

Zoetis currently has a dividend yield of 2.74%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.